{
    "title": "AstraZeneca boosts cancer portfolio with $320 mln Neogene deal",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11480469/AstraZeneca-buy-Neogene-320-mln-oncology-push.html",
    "date": "2022-11-29",
    "keywords": [
        "cancer",
        "oncology",
        "company",
        "neogene",
        "drugmaker",
        "portfolio",
        "therapy",
        "tcell",
        "receptor",
        "executive",
        "approach",
        "biotechnology",
        "tuesday",
        "pipeline",
        "companys",
        "revenue",
        "year",
        "novartis",
        "gilead",
        "discovery",
        "manufacturing",
        "experience",
        "cell",
        "capability",
        "galbraith",
        "vice",
        "president",
        "research",
        "bodys",
        "immune",
        "lab",
        "step",
        "experimental",
        "surface",
        "expertise",
        "platform",
        "area",
        "leadership",
        "footprint",
        "mean",
        "science",
        "hardtotreat",
        "carsten",
        "schumacher",
        "amsterdam",
        "santa",
        "monica",
        "california",
        "astrazeneca",
        "payment",
        "dependent",
        "meeting",
        "deal",
        "guidance",
        "quarter",
        "reporting",
        "pushkala",
        "aripaka",
        "bengaluru",
        "editing",
        "dhanya",
        "ann",
        "thoppil",
        "david",
        "goodman"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}